Home
Drugs
Blinatumomab
Clinical Trials

Clinical Trials Related to Blinatumomab

Related studies linked through entity extraction aliases.

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT

Status: TERMINATED
Phase: PHASE2

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

Status: RECRUITING
Phase: PHASE2

Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot

Status: RECRUITING
Phase: NA

Study in Adult Ph-positive ALL

Status: NOT_YET_RECRUITING
Phase: PHASE2

Blinatumomab Bridging Therapy for BALL

Status: TERMINATED
Phase: PHASE2

Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)

Status: COMPLETED
Phase: PHASE2

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Status: RECRUITING
Phase: PHASE2

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL

Status: COMPLETED
Phase: PHASE1

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

Status: TERMINATED
Phase: PHASE4

Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL

Status: WITHDRAWN
Phase: PHASE2

Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study

Status: UNKNOWN
Phase: PHASE2

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Status: RECRUITING
Phase: PHASE3

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Status: RECRUITING
Phase: PHASE1

Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant

Status: TERMINATED
Phase: PHASE2

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Status: RECRUITING
Phase: PHASE3